Wellington Management Co. LLP recently announced the acquisition of new stake in Tandem Diabetes Care Inc. (NASDAQ:TNDM). The institutional investor has increased its shareholding in the Healthcare company by 122.89% to 6.79 million shares with purchase of 3.74 million shares. This fresh investment now brings its stake to 11.29% valued currently at $671.47 million. In addition, Fidelity Management & Research Co. raised its holdings by 2.99 million to 5.29 million shares. And Invesco Advisers, Inc. has lifted its position by 109.82% or 0.87 million shares – to 1.66 million shares.
With over 0.48 million Tandem Diabetes Care Inc. (TNDM) shares trading Wednesday and a closing price of $102.37 on the day, the dollar volume was approximately $49.23 million. The shares have shown a negative weekly performance of -4.77% and its price on 07/28/20 gained nearly 3.64%. Currently, there are 59.74M common shares owned by the public and among those 57.03M shares have been available to trade.
Incidentally, analysts’ outlook for the Tandem Diabetes Care Inc. stock is 2.20 for the next 12 months.
Insiders at the company have transacted a total of 131 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 48 of these insider trades were purchases, accounting for 295,216 shares. Insider sales of the common stock occurred on 83 occasions, with total insider shares sold totaling 1,104,469 shares.
The top 3 mutual fund holders in Tandem Diabetes Care Inc. are Hartford Mid Cap Fund, Vanguard Total Stock Market Index, and Fidelity Select Medical Technolog. Hartford Mid Cap Fund owns 1.76 million shares of the company’s stock, all valued at over $174.19 million. The company sold 44397.0 shares recently to bring their total holdings to about 2.93% of the shares outstanding. Vanguard Total Stock Market Index bought 14077.0 shares to see its total holdings expand to 1.63 million shares valued at over $161.3 million and representing 2.71% of the shares outstanding. Fidelity Select Medical Technolog sold 100000.0 shares to bring its total holdings to over 1.6 million shares at a value of $158.27 million. Fidelity Select Medical Technolog now owns shares totaling to 2.66% of the shares outstanding.
Shares of Tandem Diabetes Care Inc. (NASDAQ: TNDM) opened at $99.38, up $0.61 from a prior closing price of $98.77. However, the script later closed the day at $102.37, up 3.64%. The company’s stock has a 5-day price change of -4.77% and 40.72% over the past three months. TNDM shares are trading 65.69% year to date (YTD), with the 12-month market performance up to 58.56% higher. It has a 12-month low price of $43.69 and touched a high of $108.62 over the same period. Currently, 0.48 million shares have been traded, compared to an average intraday trading volume of 1.26 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.51%, 12.73%, and 38.42% respectively.
Institutional ownership of Tandem Diabetes Care Inc. (NASDAQ: TNDM) shares accounts for 96.40% of the company’s 59.74M shares outstanding. Mutual fund holders own 38.24%, while other institutional holders and individual stakeholders account for 56.77% and 3.45% respectively.
It has a market capitalization of $6.13B and a beta (3y monthly) value of 0.55. The earnings-per-share (ttm) stands at -$0.28. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.04% over the week and 5.21% over the month.
Analysts forecast that Tandem Diabetes Care Inc. (TNDM) will achieve an EPS of -$0.24 for the current quarter, -$0.11 for the next quarter and $0.03 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.35 while analysts give the company a high EPS estimate of -$0.09. Comparatively, EPS for the current quarter was -$0.03 a year ago. Earnings per share for the fiscal year are expected to increase by 83.40%, and 106.00% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 14 brokerage firm advisors rate Tandem Diabetes Care Inc. (TNDM) as a “Moderate Buy” at a consensus score of 2.20. Specifically, 8 Wall Street analysts polled rate the stock as a buy, while 5 of the 14 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the TNDM, a number of firms have released research notes about the stock. Citigroup stated their Buy rating for the stock in a research note on July 06, 2020, with the firm’s price target at $120. Raymond James coverage for the Tandem Diabetes Care Inc. (TNDM) stock in a research note released on June 18, 2020 offered a Outperform rating with a price target of $95. SVB Leerink was of a view on April 24, 2020 that the stock is Mkt Perform, while Guggenheim gave the stock Neutral rating on March 23, 2020, issuing a price target of. Citigroup on their part issued Neutral rating on March 05, 2020.